---
title: First Slide
image: Ventas a nivel global por antivirales orales.svg
---

# Pfizer's billion-dollar monopoly

Due to the greater effectiveness of Pfizer's Paxlovid over other developments, it dominates the antiviral market, controlling 78% of sales. **In 2022, Pfizer received revenues of $18.933 billion from the sales of Paxlovid**, which corresponds to 18.87% of its total revenue.This amount is comparable to [the total economic support provided by the IMF in 2020 to 50 countries to address the ravages of the pandemic.](https://www.aa.com.tr/es/econom%C3%ADa/fmi-dona-usd-18-mil-millones-para-ayudar-a-50-naciones-a-soportar-el-impacto-del-coronavirus/1834196) It is slightly higher than the [GDP of Albania or Georgia.](https://datos.bancomundial.org/indicator/NY.GDP.MKTP.CD) Pfizer expects sales of Paxlovid to reach $8 billion by the end of 2023.


<a class="btn btn-secondary" href="https://poderlatam.org/wp-content/uploads/2023/06/tratamientos_covid.pdf" target="_blank">Download the research report</a>
<br>
